ACROBiosystems and SeromYx Systems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
and healthcare industries, has entered into a research collaboration with SeromYx Systems, specializing in advanced immunology technologies. The partnership aims to comprehensively profile the function of approved anti-CD20 monoclonal antibodies (mAbs). The collaboration leverages ACROBiosystems' recombinant human full-length CD20 virus-like particles (VLPs) and SeromYx's biophysical and cellular Fc-effector function platform to unlock new breakthrough understanding of the potential drivers of therapeutic safety and efficacy of anti-CD20 mAbs. CD20, a critical target for treating B-cell malignancies and autoimmune diseases, is selectively expressed on B-cells, allowing for effective B-cell depletion while preserving long-term immune memory. The study compared the biophysical binding and immune effector functions of Rituximab (RTX), Ofatumumab (OFA), and Obinutuzumab (OBZ), providing a detailed analysis of their mechanisms of action. Robust binding profiles and distinct Fc-effect
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- FDA tests out ‘real-time' clinical trials; AbbVie closes in on a KRAS biotech [Yahoo! Finance]Yahoo! Finance
- FDA Decisions Put Johnson & Johnson's Growth And Valuation In Focus [Yahoo! Finance]Yahoo! Finance
- Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact [Yahoo! Finance]Yahoo! Finance
- ‘American industry is winning': White House touts factory boom — how investors can ride the reshoring wave [Yahoo! Finance]Yahoo! Finance
- Poolbeg eyes transformative summer with POLB 001 data in prospect [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/14/26 - Beat
JNJ
Sec Filings
- 4/28/26 - Form 8-K
- 4/27/26 - Form 4
- 4/27/26 - Form 4
- JNJ's page on the SEC website